Robotic Remnant Total Pancreatectomy After Robotic Pancreaticoduodenectomy (with video).

Ann Surg OncolJul 4, 2026 (epub)
Case ReportGeneral SurgeryOncology (Medical)Open access

Yoshiki Fujiyama, Taiga Wakabayashi, Malek Alomari et al.

✦ AI-curated · Sources linked

Case in brief

This report details three cases of robotic remnant total pancreatectomy (R-RTP) performed after robotic pancreaticoduodenectomy (R-PD). The standardized surgical technique involved meticulous dissection and specimen removal, resulting in a mean operative time of 332 minutes and minimal blood loss. All patients achieved R0 resection and experienced no postoperative complications, with a hospital stay averaging 13.3 days.

Diagnostic / clinical pearl

Robotic remnant total pancreatectomy after robotic pancreaticoduodenectomy is technically feasible and can lead to favorable perioperative outcomes.

Why it matters

The study highlights the potential benefits of a standardized robotic approach in complex pancreatic surgeries, contributing to improved recovery and outcomes.

Source

PubMed · PMID 42401722Free full text on PubMed Central

Published in Ann Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.